Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 11, Number 2—February 2005


Malaria Epidemic and Drug Resistance, Djibouti

Christophe Rogier*Comments to Author , Bruno Pradines*, H. Bogreau*, Jean-Louis Koeck†‡, Mohamed-Ali Kamil§, and Odile Mercereau-Puijalon¶
Author affiliations: *IMTSSA-IFR48, Marseille, France; †Centre Hospitalier des Armées Bouffard, Djibouti; ‡HIA Val de Grace, Paris, France; §Ministry of Health, Djibouti; ¶Institut Pasteur, Paris, France

Main Article

Table 3

In vitro drug sensitivity of 27 Plasmodium falciparum isolates collected in Djibouti, 1999

Drugs Isolates studied (n) Mean IC50* 95% confidence interval Cut-off value % resistant isolates
Chloroquine 27 326 nmol/L 224–474 nmol/L >100 nmol/L 93
Amodiaquine 27 10.0 nmol/L 8.0–12.6 nmol/L >80 nmol/L 0
Cycloguanil 24 13 nmol/L 8–21 nmol/L >500 nmol/L 4
Pyrimethamine 25 69 nmol/L 41–117 nmol/L >2,000 nmol/L 4

*The 50% inhibitory concentration (IC50) of chloroquine diphosphate, amodiaquine, pyrimethamine dihydrochloride, and cycloguanil, i.e., the drug concentration corresponding to 50% of the uptake of 3H-hypoxanthine by the parasites in drug-free control wells, was determined by nonlinear regression analysis of log-dose/response curves. Mean IC50 and proportion of resistant isolates according to cut-off values are indicated. Data were expressed as the geometric mean IC50 and 95% confidence intervals were calculated.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO